A plasmacytoid dendritic cell (pDC) is a specialized white blood cell best known for producing large amounts of type I interferons after detecting microbial or misplaced self-derived nucleic acids. Traditionally classified among dendritic cells, pDCs contribute to antiviral defense, immune regulation, and communication between innate and adaptive immunity. Their name refers to their resemblance to antibody-secreting plasma cells when resting; the two are distinct cell types.
Morphology and distribution
Resting pDCs have a rounded shape, an eccentrically positioned nucleus, and a relatively abundant endoplasmic reticulum, consistent with their capacity for rapid protein secretion. Unlike the conspicuously branched appearance associated with activated conventional dendritic cells, resting pDCs generally lack long cellular projections. Activation can alter their shape and increase their antigen-presenting machinery.
In healthy humans, pDCs are rare in peripheral blood, generally accounting for well under 1% of circulating mononuclear cells. They also occur in bone marrow and lymphoid tissues, including lymph nodes and tonsils. During infection or inflammation, their distribution changes as cells migrate between blood and tissues.
Tissue location matters for function. A pDC encountering viral material in a lymphoid organ may receive different activating and regulatory signals from one recruited into inflamed skin or a tumor. Consequently, pDC abundance alone does not establish whether the cells are producing interferon, presenting antigen, or participating in immune suppression.
Development and identity
pDCs arise through hematopoiesis from bone-marrow progenitors. Their development depends on signaling through the growth-factor receptor FLT3 and on a characteristic transcriptional program. The transcription factor TCF4, also called E2-2, is particularly important for establishing and maintaining pDC identity. Other regulators, including IRF8, contribute to their development and function.
Their developmental relationship to other immune cells is more complex than the traditional division between “myeloid” and “lymphoid” lineages suggests. Experimental studies have identified pDC developmental potential in more than one progenitor population. The contribution of particular developmental routes varies with the organism, experimental method, and definition of a pDC. It is therefore misleading to describe all pDCs as exclusively derived from one simple lineage.
Identification
Human pDCs are commonly identified by a combination of surface features:
- High expression of CD123, the alpha chain of the interleukin-3 receptor.
- Expression of CD303, also known as BDCA-2 or CLEC4C.
- Expression of CD304, also called BDCA-4 or neuropilin-1.
- Expression of HLA-DR.
- Absence of standard markers used to identify mature T cells, B cells, monocytes, and other major blood-cell populations.
These features are usually assessed together by flow cytometry. No single marker is sufficient in every setting: activation can change marker expression, and some markers are shared with other cells.
Mouse pDCs are often identified using combinations that include B220, intermediate CD11c expression, Siglec-H, and BST2. Human and mouse marker panels are not interchangeable. BST2, in particular, can be induced on other cell types by interferon.
Nucleic-acid sensing and interferon production
The defining functional specialization of pDCs is rapid production of type I interferons, especially interferon-alpha. These secreted cytokines induce antiviral programs in nearby and distant cells and help coordinate subsequent immune responses.
Endosomal recognition
pDCs express Toll-like receptors TLR7 and TLR9 in intracellular endosomal compartments:
- TLR7 recognizes RNA-derived ligands, including material originating from certain viruses.
- TLR9 recognizes DNA containing particular CpG sequence contexts, including microbial DNA.
The relevant RNA or DNA must reach the appropriate intracellular compartment. Uptake, molecular packaging, and intracellular trafficking therefore strongly affect the response. Recognition of a nucleic acid is not determined solely by whether its sequence is foreign.
Both receptors signal through the adaptor protein MyD88. Downstream signaling activates IRF7, which drives transcription of type I interferon genes, as well as pathways that promote inflammatory cytokine production and cellular maturation. Resting pDCs maintain comparatively high IRF7 expression, helping them mount a rapid interferon response.
Effects of secreted interferon
Type I interferons bind to receptors on many cell types and trigger changes in gene expression. The resulting proteins can interfere with viral replication, improve intracellular pathogen recognition, and alter antigen processing and presentation. Interferon also influences natural killer cells, B cells, and T cells.
pDCs are not the only interferon-producing cells. Many nucleated cells can produce type I interferons through other sensing pathways. The relative importance of pDCs depends on the pathogen, infected tissue, and stage of infection; their high interferon-producing capacity does not mean that they dominate every antiviral response.
Antigen presentation and immune regulation
pDCs can act as antigen-presenting cells. They express major histocompatibility complex molecules and can present processed antigens to T cells. Activation can increase costimulatory molecules and alter their ability to stimulate adaptive immunity.
Nevertheless, pDCs should not be treated as functionally equivalent to conventional dendritic cells. Conventional dendritic-cell subsets are generally more specialized for initiating many forms of naive T-cell response. The antigen-presenting activity of pDCs varies with their activation state, antigen source, and experimental conditions.
pDCs can also participate in immune tolerance. In certain environments, they support regulatory T cells or otherwise limit immune activation. In other settings, interferon and inflammatory cytokine production amplify immune responses. These contrasting activities reflect context-dependent cellular states rather than a fixed division into inherently “protective” and “harmful” pDCs.
Roles in disease
Viral infection
pDCs can detect viral material without themselves supporting productive infection. Their early interferon response can restrict viral spread and influence the development of adaptive immunity. Some viruses evade pDC detection or inhibit their signaling pathways.
During persistent infection, prolonged interferon signaling may have effects distinct from those of an early, transient antiviral response. The consequences cannot be inferred simply from the number of pDCs in blood, particularly because cells may redistribute into tissues.
Autoimmune inflammation
pDCs are implicated in diseases involving sustained type I interferon activity, notably systemic lupus erythematosus. Self-derived nucleic acids associated with autoantibodies or other carrier molecules can enter cells and stimulate endosomal sensing pathways. This provides a mechanism by which material from the body's own cells can promote interferon production.
pDCs and interferon-associated pathways have also been studied in inflammatory skin diseases and other autoimmune conditions. Their contribution differs among diseases and disease stages. An interferon-associated pattern of gene expression does not, by itself, identify pDCs as its sole source.
Tumors and pDC-derived malignancy
pDCs occur in some tumor microenvironments, where their functions depend on local signals. They may exhibit reduced interferon production or participate in immune regulation; their presence alone does not establish an antitumor or tumor-promoting effect.
Blastic plasmacytoid dendritic cell neoplasm is a rare hematologic malignancy associated with a pDC-related cellular program. It often involves the skin and may also affect bone marrow, blood, and lymph nodes. Diagnosis requires combined assessment of morphology and multiple immunophenotypic features, because individual pDC-associated markers are not specific to this malignancy.
Historical development and research limitations
Cells resembling modern pDCs were described in lymphoid tissues before their principal immune function was established. Their plasma-cell-like appearance and location around specialized lymph-node blood vessels led to several historical names and competing interpretations of their identity. In the late 1990s, studies connected these cells with the previously recognized natural interferon-producing cells, establishing their characteristic antiviral specialization.
Modern single-cell methods have refined their classification. Some populations formerly included in human pDC preparations contain related dendritic cells or precursors with stronger T-cell-stimulating activity and different interferon-producing capacities. This finding affects the interpretation of older experiments performed on incompletely purified populations.
Major experimental limitations include differences between human and mouse pDCs, activation-dependent changes in surface markers, and depletion methods that may affect additional cell types. Cell isolation and culture conditions can also change survival and function. Reliable interpretation therefore requires distinguishing cellular identity, developmental origin, activation state, and the specific function being measured.